Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism

BenzingaDec 16 21:04

Express News | Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism

BreakingsDec 16 21:00

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Futu NewsDec 13 20:33 · Ratings

Corcept Therapeutics (CORT) Receives a Buy From Truist Financial

TipRanksDec 13 20:16 · Ratings

Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes

BenzingaDec 13 05:09

Express News | Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects

BreakingsDec 13 05:05